🔗 Share this article

While the United States continues making historic revisions to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on COVID-19 vaccinations in the global health crisis and has concentrated on possible deaths after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Agency leaders were set to unveil major revisions to the pediatric immunization program recently, bringing the US with Denmark’s immunization schedule, according to reports – a major change that would put the US out of step with a large portion of the world with little proof for public health gain. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

A Shift at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending some pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a citizenry approximately the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no apparent experience in drug development, oversight or leadership, which has been typical for past heads of the CBER. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock stated.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office authorizes thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and more, and each of these need to be supervised,” she said. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership component to the position, which manages more than 5,000 employees. “It is a huge management job, if you do it right,” she added.

Response and Controversial Programs

Regarding inquiries about Høeg’s fitness for the role and whether this assignment indicates more teamwork among agency officials on immunizations, a representative said that the “questions are based on inaccurate assumptions”.

“This background matches the responsibilities of her role,” the spokesperson explained, noting the months Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched priority voucher program, a controversial rapid therapy clearance system that allegedly worried her preceding directors. “How are these drugs being picked for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards more relaxed rules of all drugs, except for shots.”

Public History on Vaccines

Concerning vaccines, Høeg has a more documented, if problematic, track record, some experts have noted. She released a analysis using unverified public submissions to assess the rate of heart inflammation following Covid vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the incoming federal leadership encompassed changing regulations for recently developed shots and discontinuing “optional” vaccines, she stated following the vote on a podcast. At the agency, Dr. Høeg has allegedly proposed excluding teenage boys from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her preconceived notions and reverse-engineers to fit the data in a highly misleading, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of fellow skeptics, {like|